Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

This phase 3a, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of once-weekly cagrilintide semaglutide (CagriSema) in adults with overweight or obesity and type 2 diabetes. The study involved 1206 patients across 12 countries, randomized to receive either CagriSema (2.4 mg each) or placebo for 68 weeks. Results showed a mean weight loss of 13.7% in the CagriSema group compared to 3.4% in the placebo group, with 83.6% of CagriSema patients achieving ≥5% weight loss. Glycemic control improved significantly, with 73.5% of CagriSema patients reaching a glycated hemoglobin level ≤6.5%. Gastrointestinal adverse events were common but mostly mild or moderate. The findings support CagriSema as a promising treatment for weight management and glycemic control in this population.

This phase 3a, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of once-weekly cagrilintide semaglutide (CagriSema) in adults with overweight or obesity and type 2 diabetes. The study involved 1206 patients across 12 countries, randomized to receive either CagriSema (2.4 mg each) or placebo for 68 weeks. Results showed a mean weight loss of 13.7% in the CagriSema group compared to 3.4% in the placebo group, with 83.6% of CagriSema patients achieving ≥5% weight loss. Glycemic control improved significantly, with 73.5% of CagriSema patients reaching a glycated hemoglobin level ≤6.5%. Gastrointestinal adverse events were common but mostly mild or moderate. The findings support CagriSema as a promising treatment for weight management and glycemic control in this population.